. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Lancet Oncol. 2014 Nov 12;15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3

Table 2.

Sensitivity analyses of survival outcomes for XELOX versus FOLFOX in all treated patients

	Hazard ratio (95% CI)	p-value
*XELOX versus FOLFOX*^
Disease-free survival	1·00 (0·90–1·11)	0·98
Relapse-free survival	0·99 (0·89–1·10)	0·85
Overall survival	1·12 (0·97–1·28)	0·11
*XELOX versus capecitabine monotherapy**
Disease-free survival	0·74 (0·64–0·86)	<0·0001
Relapse-free survival	0·73 (0·63–0·85)	<0·0001
Overall survival	0·75 (0·63–0·88)	0·0007

Adjusted for use of bevacizumab.

XELOX=capecitabine plus oxaliplatin. FOLFOX=leucovorin and fluorouracil plus oxaliplatin.